| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-058 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 广西柳药集团股份有限公司 关于以集中竞价交易方式首次回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次回购股份的情况公告如下： 2025 年 8 月 6 日，公司通过集中竞价交易方式首次回购股份数量为 54.45 万 股，已回购股份占公司目前总股本的比例为 0.14%，回购成交的最高价为 18.36 元 /股、最低价为 18.29 元/股，已支付的总金额为 998.28 万元（不含交易费用）。 上述回购股份进展符合相关法律法规的规定及公司回购股份方案的要求。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | | --- | --- | --- | --- | --- | --- ...

格隆汇8月6日丨柳药集团(603368.SH)公布，2025年8月6日，公司通过集中竞价交易方式首次回购股份 数量为54.45万股，已回购股份占公司目前总股本的比例为0.14%，回购成交的最高价为18.36元/股、最 低价为18.29元/股，已支付的总金额为998.28万元（不含交易费用）。 ...

公告显示，此次回购拟耗资1亿元至2亿元，回购价格上限不超过25.70元/股(含)，回购期限为自董事会 审议通过本次回购方案之日起不超过12个月。依照回购价格上限测算，本次回购的股份数量为389万股 —778万股，回购股份占公司总股本比例为0.98%—1.96%。 公开资料显示，柳药集团旗下已拥有40余家公司，形成以"医药批发、医药零售、医药工业为主业，供 应链增值服务、医药互联网服务、终端健康服务等创新业务协同发展"的综合性医药大健康产业集团。 中证报中证网讯(王珞)近日，柳药集团（603368）发布公告称，基于对公司未来发展前景的信心和对公 司长期价值的高度认可，为推动公司股票价值的合理回归，稳定投资者预期，增强市场信心，维护公司 和全体股东的利益，并进一步落实"提质增效重回报"行动方案，同时为完善公司长效激励机制，充分调 动公司员工的积极性，促进公司健康可持续发展，在综合考虑公司经营情况、财务状况以及未来盈利能 力等情况下，公司拟通过集中竞价交易方式回购部分公司A股股份，在未来适宜时机用于实施股权激励 及/或员工持股计划。 ...

Summary of Key Points Core Viewpoint - The company, Guangxi Liuyuan Group Co., Ltd., has announced a share repurchase plan to enhance investor confidence and implement employee stock ownership plans, with a total repurchase amount ranging from RMB 100 million to RMB 200 million [2][33]. Group 1: Repurchase Plan Details - The repurchase amount will not be less than RMB 100 million and not exceed RMB 200 million [2]. - The funding sources for the repurchase will be the company's own funds and self-raised funds, with a loan commitment from Industrial Bank Co., Ltd. for up to RMB 180 million [17]. - The repurchase price will not exceed RMB 25.70 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [2][16]. - The repurchase will be conducted through centralized bidding and is expected to be completed within 12 months from the board's approval [3][11]. Group 2: Purpose and Use of Repurchased Shares - The purpose of the repurchase is to stabilize investor expectations, enhance market confidence, and implement employee stock ownership plans [8]. - If the repurchased shares are not used for the intended purposes within three years, they will be canceled [2][22]. Group 3: Shareholder and Management Plans - As of the board's decision date, there are no plans for share reduction by the company's directors, supervisors, and major shareholders in the next three to six months [4][20]. - The board approved the repurchase plan with unanimous consent, and it does not require shareholder meeting approval [7]. Group 4: Financial Impact and Company Status - As of March 31, 2025, the company's total assets were RMB 20.997 billion, and the repurchase amount will have a minimal impact on its financials, accounting for approximately 0.95% to 2.53% of various financial metrics [18][19]. - The company maintains a debt ratio of 60.87%, indicating that the repurchase will not significantly affect its debt repayment capacity [19]. Group 5: Progress and Compliance - As of July 31, 2025, the company has not yet repurchased any shares through the announced plan [34]. - The company will continue to comply with relevant regulations and disclose progress on the repurchase plan regularly [36].

证券代码：603368 证券简称：柳药集团 公告编号：2025-057 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日召开第 五届董事会第二十七次会议，审议通过了《关于以集中竞价交易方式回购股份方 案的议案》，同意公司使用自有资金和自筹资金通过集中竞价交易方式回购部分公 司 A 股股份，在未来适宜时机用于实施股权激励及/或员工持股计划。本次回购资 金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含）；回购价 格上限不超过人民币 25.70 元/股（含）；回购期限为自董事会审议通过本次回购方 案之日起不超过 12 个月。具体内容详见公司分别于 2025 年 7 月 26 日、2025 年 8 月 5 日在上海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方 式回购股份方案的公告》（公告编号：2025-053）、《关于以集中竞价交易方式回购 股份的回购报告书》（公告编号：2025-056）。 转债代码：113563 转债简称：柳药转债 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with a total repurchase amount ranging from RMB 100 million to RMB 200 million, aimed at implementing equity incentives and/or employee stock ownership plans in the future [1][3][11]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 100 million and not exceed RMB 200 million [1][3]. - The funding sources for the repurchase will be the company's own funds and self-raised funds, with a loan commitment of up to RMB 180 million from a bank [1][10]. - The maximum repurchase price is set at RMB 25.70 per share, which is 150% of the average trading price over the previous 30 trading days [1][9]. Repurchase Execution - The repurchase will be conducted through a centralized bidding method and is expected to be completed within 12 months from the board's approval [2][5]. - The estimated number of shares to be repurchased ranges from approximately 389,110 shares to 778,210 shares, accounting for 0.98% to 1.96% of the total share capital [7][8]. Purpose and Impact - The repurchased shares will be used for equity incentives and/or employee stock ownership plans, enhancing investor confidence and aligning the interests of shareholders and employees [5][11]. - The company believes that the repurchase will not significantly impact its operations, financial status, or future development [11][12]. Shareholder Information - As of the board's approval date, major shareholders, including directors and actual controllers, have no plans to reduce their holdings in the next three to six months [2][13]. - The company has established a dedicated securities account for the repurchase, ensuring compliance with regulations [16].

证券日报网讯8月4日晚间，柳药集团（603368）发布公告称，截至2025年7月31日，公司尚未通过集中 竞价交易方式回购公司股份。 ...

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-056 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 ● 回购股份方式：集中竞价交易方式。 ● 回购股份期限：自董事会审议通过本次回购方案之日起不超过 12 个月。 ● 相关股东是否存在减持计划：经公司问询，截至董事会审议通过本次回购 方案日，公司董监高、控股股东暨实际控制人在未来 3 个月、未来 6 个月均暂无 减持公司股份计划。若前述主体未来拟实施股份减持计划，公司将按照相关法律 法规的规定及时履行信息披露义务。 ● 相关风险提示： 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 10,000 万元（含），不超过人民币 20,000 万 元（含）。 ● 回购股份资金来源：广西柳药集团股份有限公司（以下简称"公司"）自 有资金和自筹资金。公司已取得兴业银行股份有限公司柳州分 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-057 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 7 月 7 | 25 | 日~2026 | 年 | 月 | 24 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 0万股 | | | | | | | 累计已回购股数占总股本比例 | 0 ...